scholarly journals Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

2019 ◽  
Vol 79 (06) ◽  
pp. 605-617 ◽  
Author(s):  
Andreas Schneeweiss ◽  
Carsten Denkert ◽  
Peter A. Fasching ◽  
Carlo Fremd ◽  
Oleg Gluz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Strategies ◽  
Routine Practice ◽  
Daily Routine ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches ◽  
Tumour Biology ◽  
Therapeutic Concepts

AbstractThe rapid increase in knowledge in tumour biology and tumour pathogenesis of triple-negative breast cancer (TNBC) has resulted in new therapeutic approaches and new therapeutic concepts for treatment. For years, TNBC has been considered to be a difficult-to-treat tumour due to its generally aggressive tumour biology and in view of limited therapeutic options. The risk of recurrence and metastasis is higher than in the case of other breast cancer subtypes of the same stage. In addition to surgery and radiation in the curative situation, systemic chemotherapy with anthracyclines and/or taxanes is still the therapy of choice. New therapeutic approaches are based on the knowledge that TNBC is a molecularly very heterogeneous disease. Research groups are working to classify TNBC better and better on a molecular level and use this molecular subtyping as the basis for new therapeutic strategies. The most promising new approaches and considerations regarding the therapy of TNBCs are shown below. In addition, the current therapeutic strategies are discussed using a fictitious case history, taking the current data and the resultant therapeutic consequence into account.

Triple negative breast cancer: new therapeutic approaches andBRCAstatus

Apmis ◽  
2018 ◽  
Vol 126 (5) ◽  
pp. 371-379 ◽  
Author(s):  
Gamze Guney Eskiler ◽  
Gulsah Cecener ◽  
Unal Egeli ◽  
Berrin Tunca
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

scholarly journals Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Antonio Marra ◽  
Dario Trapani ◽  
Giulia Viale ◽  
Carmen Criscitiello ◽  
Giuseppe Curigliano
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Therapeutic Approaches ◽  
Minimal Residual Disease Monitoring ◽  
Anticancer Treatment ◽  
Immune Contexture

Abstract Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across TNBC subtypes, prompting the implementation of biomarker-driven therapeutic approaches. However, biomarker-based treatments as well as immune checkpoint inhibitor-based immunotherapy have provided contrasting and limited results so far. Accordingly, a better characterization of the genomic and immune contexture underpinning TNBC, as well as the translation of the lessons learnt in the metastatic disease to the early setting would improve patients’ outcomes. The application of multi-omics technologies, biocomputational algorithms, assays for minimal residual disease monitoring and novel clinical trial designs are strongly warranted to pave the way toward personalized anticancer treatment for patients with TNBC.

scholarly journals Therapeutic Strategies in Triple-Negative Breast Cancer

Breast Care ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 6-7 ◽  
Author(s):  
Angelo Paradiso ◽  
Christian F. Singer
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Strategies

Multifunctional nanodiamonds-based nanoplatform for enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer via autophagy regulation strategy

Nanoscale ◽  
2021 ◽  
Author(s):  
Xinyue Cui ◽  
Zhaoyuan Liang ◽  
Jianqing Lu ◽  
Xuan Wang ◽  
Fan Jia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Strategies ◽  
Biological Behavior ◽  
Therapeutic Resistance ◽  
Multiple Treatments ◽  
Mild Temperature

Due to the aggressive biological behavior, lacking of specific targets and unconquered therapeutic resistance of Triple Negative Breast Cancer (TNBC), current therapeutic strategies were still limited. Combining multiple treatments have...

Novel Therapeutic Strategies of Triple-Negative Breast Cancer

2020 ◽  
pp. 157-198
Author(s):  
Guifei Li ◽  
Hui Yao ◽  
Shichao Yan ◽  
Shujun Fu ◽  
Xiyun Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Strategies ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

scholarly journals Novel therapeutic strategies in the treatment of triple-negative breast cancer

2017 ◽  
Vol 9 (7) ◽  
pp. 493-511 ◽  
Author(s):  
Karima Oualla ◽  
Heba M. El-Zawahry ◽  
Banu Arun ◽  
James M. Reuben ◽  
Wendy A. Woodward ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Therapeutic Strategies ◽  
Her2 Status ◽  
Biological Complexity ◽  
Epidermal Growth ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

Advances in Therapeutic Approaches for Triple Negative Breast Cancer

2020 ◽  
Author(s):  
Reshma Mahtani ◽  
Muaiad Kittaneh ◽  
Kevin Kalinsky ◽  
Eleftherios Mamounas ◽  
Sunil Badve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Approaches
Sign in / Sign up

Export Citation Format

Share Document